Leap Therapeutics (NASDAQ:LPTX) Now Covered by Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Leap Therapeutics (NASDAQ:LPTX) in a research report report published on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $8.00 price target on the stock.

LPTX has been the topic of several other reports. Robert W. Baird decreased their target price on shares of Leap Therapeutics from $11.00 to $9.00 and set an outperform rating on the stock in a research note on Tuesday, March 19th. HC Wainwright cut their price objective on Leap Therapeutics from $7.00 to $5.50 and set a buy rating on the stock in a research report on Tuesday, May 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus target price of $10.40.

Leap Therapeutics Price Performance

NASDAQ:LPTX opened at $1.96 on Friday. Leap Therapeutics has a 1 year low of $1.24 and a 1 year high of $5.00. The business has a fifty day simple moving average of $2.53 and a two-hundred day simple moving average of $2.87. The company has a market capitalization of $50.18 million, a P/E ratio of -0.82 and a beta of 0.41.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.06. As a group, analysts anticipate that Leap Therapeutics will post -1.66 earnings per share for the current year.

Hedge Funds Weigh In On Leap Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LPTX. 683 Capital Management LLC grew its stake in Leap Therapeutics by 60.7% during the third quarter. 683 Capital Management LLC now owns 490,000 shares of the company’s stock valued at $676,000 after acquiring an additional 185,001 shares in the last quarter. Acuta Capital Partners LLC purchased a new stake in Leap Therapeutics during the third quarter valued at approximately $489,000. Key Client Fiduciary Advisors LLC lifted its position in Leap Therapeutics by 43.3% in the third quarter. Key Client Fiduciary Advisors LLC now owns 227,273 shares of the company’s stock worth $314,000 after buying an additional 68,676 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Leap Therapeutics by 111.7% in the 1st quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock worth $2,308,000 after acquiring an additional 457,904 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Leap Therapeutics by 349.3% during the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock valued at $750,000 after buying an additional 219,563 shares during the period. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.